Eprosartan mesylate
CAS: 144143-96-4
Ref. 3D-FE61516
1g | 484,00 € | ||
2g | 738,00 € | ||
100mg | 136,00 € | ||
250mg | 206,00 € | ||
500mg | 309,00 € |
Informação sobre produto
- 2-Thiophenepropanoic acid, α-[[2-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazol-5-yl]methylene]-, (E)-, monomethanesulfonate
- 2-Thiophenepropanoic acid, α-[[2-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazol-5-yl]methylene]-, (αE)-, methanesulfonate (1:1)
- 2-Thiophenepropanoic acid, α-[[2-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazol-5-yl]methylene]-, (αE)-, monomethanesulfonate
- 4-({2-butyl-5-[(1E)-2-carboxy-3-thiophen-2-ylprop-1-en-1-yl]-1H-imidazol-1-yl}methyl)benzoic acid methanesulfonate
- 4-[[2-Butyl-5-(2-Carboxy-3-Thiophen-2-Yl-Prop-1-Enyl)-Imidazol-1-Yl]Methyl]Benzoic Acid Mesylate
- Eprosartan Methanesulfonate
- Skf 108566J
Eprosartan mesylate is an angiotensin II receptor antagonist and a prodrug of eprosartan. It is used in the treatment of hypertension, congestive heart failure, and for the prophylaxis of organ rejection in renal transplantation. This drug has been shown to inhibit the activation of nuclear factor-κB (NF-κB) and the production of inflammatory cytokines such as growth factor-β1 (GF-β1). Eprosartan mesylate has also been shown to have a beneficial effect on experimental models of type 2 diabetes and metabolic disorders. In clinical trials, it was found that losartan had similar effects on lowering blood pressure as eprosartan mesylate, but the combination increased blood pressure more than either agent alone. Eprosartan mesylate should not be taken with drugs that are metabolized by cytochrome P450 enzymes because they may lead to serious adverse effects such
Propriedades químicas
Consulta técnica sobre: 3D-FE61516 Eprosartan mesylate
Se desejar solicitar um orçamento ou fazer uma encomenda, por favor, adicione os produtos ao seu carrinho e depois solicite um orçamento ou encomenda a partir do carrinho. É mais rápido, mais barato e poderá beneficiar-se dos descontos e outras vantagens disponíveis.